Valence8 US’s Bristol-Myers Squibb BMY Stock Holding History

Valence8 US’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-17,785	Closed	-$920K	–	24
2024 Q3	$920K	Buy	+17,785	New	+$834K	0.38%	12

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Valence8 US's BMY Position: Q4 2024 in Review

Valence8 US sold out of Bristol-Myers Squibb (BMY) in Q4 2024, closing a stake of 17,785 shares — an estimated $920K sold.

Valence8 US first reported a position in BMY in Q3 2024 and held it in 1 quarter. The position peaked at $920K in Q3 2024. 2,486 funds tracked by Wall St. Rank hold BMY as of Q4 2024.

Valence8 US reported no remaining Bristol-Myers Squibb position as of Q4 2024 after selling out during the quarter.
Valence8 US sold 17,785 Bristol-Myers Squibb shares in Q4 2024, an estimated $920K.
Valence8 US first reported a position in Bristol-Myers Squibb in Q3 2024 and held it in 1 quarter.
Valence8 US's Bristol-Myers Squibb position peaked at $920K in Q3 2024.
2,486 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2024.

Based on Valence8 US's 13F filing for Q4 2024, filed 12 Feb 2025.